• Occurrence of study related adverse events (defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment [ Time Frame: Until week 24 ] [ Designated as safety issue: Yes ]
  
• Feasibility to manufacture CART-19 cells from patient apheresis products [ Designated as safety issue: No ]
  
• Engraftment as defined by duration of in vivo survival of CART-19 cells [ Designated as safety issue: No ]
  
• New onset secondary malignancies [ Designated as safety issue: No ]
  

• Anti-tumor responses to CART-19 cell infusions [ Designated as safety issue: No ]
  
• Overall survival and cause of death [ Designated as safety issue: No ]
  
• Correlation of in vitro killing assays of CART-19 cells against patient tumor with clinical response in patients with stored or accessible tumor cells [ Designated as safety issue: No ]
  
• Host immunity against the murine anti-CD19 or other elements of the transgene or vector such as VSV-G, and correlation with loss of detectable CART-19 (loss of engraftment) [ Designated as safety issue: No ]
  
• General anti-tumor immunity [ Time Frame: Baseline and post-infusion ] [ Designated as safety issue: No ]
  
• Relative survival of CART-19 TCR zeta and TCR zeta:4-1BB cells over time (in subjects infused with mixture of T cells) [ Designated as safety issue: No ]
  
• Relative subsets of CART-19 T cells (Tcm, Tem, and Treg) [ Designated as safety issue: No ]
  
• Relative engraftment of CART-19 cells expressing TCR zeta or TCR zeta:4-1BB domains [ Designated as safety issue: No ]
  

PRIMARY OBJECTIVES:

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).

II. Determine duration of in vivo survival of CART-19 cells. RT-PCR analysis of whole blood will be used to detect and quantify survival of CART-19 TCR zeta:4-1BB and TCR zeta cells over time.

SECONDARY OBJECTIVES:

I. For patients with detectable disease, measure anti-tumor response due to CART-19 cell infusions.

II. To determine if the 4-1BB transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-19 TCR zeta:4-1BB and TCR zeta cells over time.

III. Estimate relative trafficking of CART-19 cells to tumor in bone marrow and lymph nodes.

IV. For patients with stored or accessible tumor cells (such as patients with active CLL, ALL, etc) determine tumor cell killing by CART-19 cells in vitro.

V. Determine if cellular or humoral host immunity develops against the murine anti-CD19, and assess correlation with loss of detectable CART-19 (loss of engraftment).

VI. Determine the relative subsets of CART-19 T cells (Tcm, Tem, and Treg).

OUTLINE: Patients are assigned to 1 of 2 groups according to order of enrollment.

Group 1 (Patients 1-5): Patients receive anti-CD19-CAR retroviral vector-transduced autologous T cells with 41BB-gamma vector on days 0,1, 2, and 11 in the absence of disease progression or unacceptable toxicity.

Group 2 (Patients 6-10): Patients receive anti-CD19-CAR retroviral vector-transduced autologous T cells with either 41BB-gamma vector or TCR zeta vector on days 0,1, 2, and 11 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 13 years.